{"id":"W2946983074","doi":"10.1200/jco.2019.37.15_suppl.tps5600","title":"ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Oncology; Internal medicine; Carboplatin; Trabectedin; Pembrolizumab; Bevacizumab; Clinical endpoint; Phases of clinical research; Clinical trial; Chemotherapy; Surgery; Cancer; Immunotherapy; Cisplatin; Soft tissue sarcoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002931545,0.003059809,0.003637645,0.0007366893,0.0005176364,0.001516567,0.001617132,0.002677886,0.01023462],"category_scores_gemma":[0.001827936,0.001257896,0.00191494,0.0005898845,0.001726741,0.001641379,0.0006065591,0.004448673,0.001843989],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001175062,"about_ca_system_score_gemma":0.002167602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009837535,"about_ca_topic_score_gemma":0.00240259,"domain_scores_codex":[0.9993113,0.0003480668,0.00002854633,0.0001259072,0.00005088351,0.0001352393],"domain_scores_gemma":[0.9990156,0.0001986552,0.0002057636,0.00009761989,0.00005201422,0.0004303439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9534076,0.0252433,0.0006156124,0.0006831768,0.0004797983,0.00003578894,0.00005814039,0.0004679462,0.004088898,0.0001716384,0.001332053,0.01341604],"study_design_scores_gemma":[0.9442405,0.05355752,0.000772343,0.00001565525,0.0001627904,0.00002641462,0.000009939376,0.0002514514,0.0002888003,0.00009683984,0.0005665337,0.00001117245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.970273,0.003844032,0.001337536,0.001083162,0.0007339488,0.01512779,0.00376059,0.0004502333,0.003389787],"genre_scores_gemma":[0.9437183,0.004153415,0.006866082,0.00306772,0.0009249281,0.02440931,0.005811584,0.0001682976,0.01088035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01023462,"threshold_uncertainty_score":0.03423822,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.128313264709569,"score_gpt":0.4499898754624252,"score_spread":0.3216766107528563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}